Comparative effectiveness of second-generation antidepressants for accompanying anxiety, insomnia, and pain in depressed patients: a systematic review
Depression and Anxiety, 05/07/2012Thaler KJ et al.
Evidence guiding the selection of an second–generation antidepressant based on accompanying symptoms of depression is limited. Very few trials were designed and adequately powered to answer questions about accompanying symptoms; analyses were generally of subgroups in larger major depressive disorder trials.
The authors conducted searches in multiple databases including MEDLINE, Embase, the Cochrane Library, International Pharmaceutical Abstracts, and PsycINFO, from 1980 through August 2011 and reviewed reference lists of pertinent articles.
They dually reviewed abstracts, full-text articles, and abstracted data.
They included randomized, head-to-head trials of SGAs of at least 6 weeks’ duration.
They grouped SGAs into three classes for the analysis: selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors, and others.
They graded the strength of the evidence as high, moderate, low, or very low based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group (GRADE) approach.
The authors located 19 head-to-head trials in total: 11 on anxiety, six on insomnia, and four on pain.
For the majority of comparisons, the strength of the evidence was moderate or low: evidence is weakened by inconsistency and imprecision.
For treating anxiety, insomnia, and pain moderate evidence suggests that the SSRIs do not differ.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.